Compounds > dehydrodieugenol
Page last updated: 2024-11-08

dehydrodieugenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dehydrodieugenol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID165225
CHEMBL ID182629
CHEBI ID4361
SCHEMBL ID5320878
MeSH IDM0457179

Synonyms (22)

Synonym
dehydrodieugenol
4433-08-3
2,2'-biphenyldiol, 5,5'-diallyl-3,3'-dimethoxy-
CHEMBL182629
bis-eugenol
chebi:4361 ,
2-(2-hydroxy-3-methoxy-5-prop-2-enylphenyl)-6-methoxy-4-prop-2-enylphenol
AC1L4WB6 ,
AC1Q79LE ,
AB00115914-01
SCHEMBL5320878
bieugenol
KETPSFSOGFKJJY-UHFFFAOYSA-N
5,5'-diallyl-3,3'-dimethoxy[1,1'-biphenyl]-2,2'-diol #
[1,1'-biphenyl]-2,2'-diol, 3,3'-dimethoxy-5,5'-di-2-propenyl-
4-allyl-2-(5-allyl-2-hydroxy-3-methoxy-phenyl)-6-methoxy-phenol
dieugenol
SR-01000500269-1
sr-01000500269
DTXSID80196137
Q27106349
3,3'-dimethoxy-5,5'-di-2-propen-1-yl-[1,1'-biphenyl]-2,2'-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID648731Antibacterial activity against methicillin-resistant Staphylococcus aureus 15187 after 24 hrs by micro dilution method2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID648736Antifungal activity against Candida albicans ATCC 900282012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID648739Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID648737Antifungal activity against Aspergillus fumigatus LSI-II2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID648733Antibacterial activity against Staphylococcus aureus ATCC 29213 treated for 24 hrs followed by compound treated at 2 to 16 times MIC measured after 24 hrs by micro dilution method2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID648740Antiproliferative activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID648734Antibacterial activity against methicillin-resistant Staphylococcus aureus 15187 treated for 24 hrs followed by compound treated at 2 to 16 times MIC measured after 24 hrs by micro dilution method2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID648738Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID648735Antibacterial activity against vancomycin-resistant Enterococcus treated for 24 hrs followed by compound treated at 2 to 16 times MIC measured after 24 hrs by micro dilution method2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID247905Cytotoxicity of compound against human liver tumor cell line (Hep-G2) was determined2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Cytotoxic neolignans: an SAR study.
AID648730Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by micro dilution method2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID1491172Inhibition of yeast alpha-glucosidase using p-nitrophenyl-alpha-glucopyranoside as substrate measured after 30 mins
AID648732Antibacterial activity against vancomycin-resistant Enterococcus after 24 hrs by micro dilution method2012European journal of medicinal chemistry, May, Volume: 51Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.
AID1491171Inhibition of yeast alpha-glucosidase at 1.5 uM using p-nitrophenyl-alpha-glucopyranoside as substrate measured after 30 mins relative to control
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (23.08)29.6817
2010's6 (46.15)24.3611
2020's4 (30.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.18 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.0710aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0710nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
pomiferin
pomiferin: structure in first source		2.0110isoflavanones
1,2-dipalmitoylphosphatidylcholine
1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.		2.610
acrolein
[no description available]		2.4220enalherbicide;
human xenobiotic metabolite;
toxin
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		2.0710cyclic ketone;
erythromycin
2,2'-biphenol
biphenyl-2,2'-diol : A member of the class of hydroxybiphenyls carrying hydroxy groups at positions 2 and 2'.		2.0210hydroxybiphenyls
chavicol
4-allylphenol: an inhibitor of aryl-alcohol oxidase; has free radical scavenging activity. chavicol : A phenylpropanoid that is phenol substituted by a prop-2-enyl group at position 4.		2.0210phenols;
phenylpropanoid
magnolol
[no description available]		2.4520biphenyls
honokiol
[no description available]		2.0210biphenyls
tesmilifene
[no description available]		2.610diarylmethane
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		3.4870
linoleic acid
Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.		2.0110octadecadienoic acid;
omega-6 fatty acid		algal metabolite;
Daphnia galeata metabolite;
plant metabolite
beta carotene
beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.		2.0110carotenoid beta-end derivative;
cyclic carotene		antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A
coniferaldehyde
coniferaldehyde: from aqueous extract of Senra incana. coniferyl aldehyde : A member of the class of cinnamaldehydes that is cinnamaldehyde substituted by a hydroxy group at position 4 and a methoxy group at position 3.		2.4220cinnamaldehydes;
guaiacols;
phenylpropanoid		antifungal agent;
plant metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Asthma, Bronchial
[description not available]		02.2510
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		02.2510
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		07.2510
Pneumonia
Infection of the lung often accompanied by inflammation.		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0810
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		02.0810